Phase II study of liposomal doxorubicin in combination with trastuzumab plus cyclophosphamide followed by docetaxel plus trastuzumab as primary systemic therapy for patients with locally advanced breast cancer with HER2 overexpression or amplification.

Trial Profile

Phase II study of liposomal doxorubicin in combination with trastuzumab plus cyclophosphamide followed by docetaxel plus trastuzumab as primary systemic therapy for patients with locally advanced breast cancer with HER2 overexpression or amplification.

Recruiting
Phase of Trial: Phase II

Latest Information Update: 26 Feb 2018

At a glance

  • Drugs Doxorubicin (Primary) ; Cyclophosphamide; Docetaxel; Trastuzumab
  • Indications Breast cancer
  • Focus Therapeutic Use
  • Acronyms MYETT
  • Most Recent Events

    • 26 Feb 2018 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top